PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 9261213-10 1997 In contrast, P-glycoprotein functions for the secretion of drugs into the intestinal lumen, thereby decreasing intestinal absorption of an immunosuppressive, cyclosporin A and a 5-HT3 receptor antagonist, azasetron. Cyclosporine 158-171 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 13-27 8953513-8 1996 When in-vivo intestinal absorption was evaluated by the rat jejunal loop method, with simultaneous intravenous administration of a P-glycoprotein inhibitor, cyclosporin, intestinal absorption of both acebutolol and vinblastine increased 2.6- and 2.2-fold, respectively, but no such enhancement was observed in the absorption of acetamide. Cyclosporine 157-168 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 131-145 9264327-5 1997 The colchicine and vinblastine uptake rate was increased by cyclosporin A, an inhibitor of the drug efflux pump P-glycoprotein, which is expressed at the blood-brain barrier. Cyclosporine 60-73 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 112-126 8895755-9 1996 Infusion of cyclosporine (6 microM), an inhibitor of both P-gp and MOAT, significantly blocked both E(2)17G cholestasis and biliary excretion, such that 16 micromol E(2)17G decreased the bile flow only 15-20%. Cyclosporine 12-24 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 58-62 8944692-6 1996 Daunorubicin, vinblastine, etoposide, cyclosporin, and PSC-833, substrates/modulators of P-glycoprotein, were also potent inhibitors of E217G transport, and E217G competitively inhibited the ATP-dependent transport of daunorubicin. Cyclosporine 38-49 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 89-103 7598699-0 1995 Effect of the p-glycoprotein inhibitor, cyclosporin A, on the distribution of rhodamine-123 to the brain: an in vivo microdialysis study in freely moving rats. Cyclosporine 40-53 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 14-28 8851819-11 1996 The modulation of Pgp levels by IMM did not parallel the changes in 3A levels, indicating that Pgp regulation is most likely due to a direct effect of the cyclosporin rather than a co-regulation mechanism linked to 3A or P4501A modulation. Cyclosporine 155-166 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 95-98 8928836-0 1996 Cyclosporin A treatment induces overexpression of P-glycoprotein in the kidney and other tissues. Cyclosporine 0-13 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 50-64 8928836-3 1996 Interaction of CsA with PGP was further investigated by treating rats with daily subcutaneous injections of CsA (10 mg.kg-1.day-1). Cyclosporine 15-18 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 24-27 8928836-5 1996 This induction was a reversible process, since after cessation of CsA administration PGP levels declined to reach values similar to those of the control groups. Cyclosporine 66-69 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 85-88 8928836-8 1996 These results demonstrate that CsA induces reversible overexpression of PGP in the rat. Cyclosporine 31-34 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 72-75 7598699-2 1995 This study examined the effect of a p-glycoprotein inhibitor, cyclosporin A, on the distribution to the brain of a p-glycoprotein substrate, rhodamine-123, in freely moving rats using intracerebral microdialysis coupled with on-line HPLC analysis. Cyclosporine 62-75 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 36-50 7598699-2 1995 This study examined the effect of a p-glycoprotein inhibitor, cyclosporin A, on the distribution to the brain of a p-glycoprotein substrate, rhodamine-123, in freely moving rats using intracerebral microdialysis coupled with on-line HPLC analysis. Cyclosporine 62-75 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 115-129 7599379-3 1995 Cyclosporin A (CSA) is a potent inhibitor of Pgp. Cyclosporine 0-13 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 45-48 7599379-3 1995 Cyclosporin A (CSA) is a potent inhibitor of Pgp. Cyclosporine 15-18 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 45-48 7599379-6 1995 CONCLUSION: The mechanism of protection by CSA and its relationship to Pgp remain uncertain. Cyclosporine 43-46 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 71-74 7986214-0 1994 In vivo evidence for ATP-dependent and P-glycoprotein-mediated transport of cyclosporin A at the blood-brain barrier. Cyclosporine 76-89 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 39-53 7986214-5 1994 The ATP-dependent and QND-sensitive efflux of CsA from the brain strongly indicates that P-gp in the brain capillary endothelial cells functions as an efflux pump under the physiological state, and that P-gp-mediated efflux of CsA is a major mechanism of the restricted transfer from blood into the brain. Cyclosporine 46-49 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 203-207 7986214-1 1994 To evaluate the significance of P-glycoprotein (P-gp)-mediated active efflux on the blood-brain barrier (BBB) permeability of cyclosporin A (CsA) in vivo, we investigated the effects of ATP depletion in the brain and of a multidrug-resistant (MDR) reversing agent on the transport of CsA across the BBB. Cyclosporine 126-139 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 48-52 7986214-5 1994 The ATP-dependent and QND-sensitive efflux of CsA from the brain strongly indicates that P-gp in the brain capillary endothelial cells functions as an efflux pump under the physiological state, and that P-gp-mediated efflux of CsA is a major mechanism of the restricted transfer from blood into the brain. Cyclosporine 227-230 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 89-93 7986214-5 1994 The ATP-dependent and QND-sensitive efflux of CsA from the brain strongly indicates that P-gp in the brain capillary endothelial cells functions as an efflux pump under the physiological state, and that P-gp-mediated efflux of CsA is a major mechanism of the restricted transfer from blood into the brain. Cyclosporine 227-230 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 203-207 7986214-1 1994 To evaluate the significance of P-glycoprotein (P-gp)-mediated active efflux on the blood-brain barrier (BBB) permeability of cyclosporin A (CsA) in vivo, we investigated the effects of ATP depletion in the brain and of a multidrug-resistant (MDR) reversing agent on the transport of CsA across the BBB. Cyclosporine 141-144 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 48-52 7986214-5 1994 The ATP-dependent and QND-sensitive efflux of CsA from the brain strongly indicates that P-gp in the brain capillary endothelial cells functions as an efflux pump under the physiological state, and that P-gp-mediated efflux of CsA is a major mechanism of the restricted transfer from blood into the brain. Cyclosporine 46-49 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 89-93 7913684-6 1994 Labeling of the immunoprecipitated P-glycoprotein was inhibited by acridine orange, verapamil, and by cyclosporin A. Cyclosporine 102-115 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 35-49 29530563-6 2018 In addition, while the P-gp inhibitor CsA increased the intestinal uptake of ranitidine in both male and female rats, a greater extent of intestinal transport modulation was observed in males compared to females. Cyclosporine 38-41 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 23-27 7987977-14 1994 The action of cyclosporine and S 9788 on the retention of daunorubicinol proves that at least a part of the efflux of C-13 alcohol metabolites of anthracyclines is mediated by Pgp. Cyclosporine 14-26 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 176-179 7987977-15 1994 This study shows that S 9788, cyclosporine, and verapamil are MDR modulators in hepatocytes with high-level Pgp expression. Cyclosporine 30-42 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 108-111 1349283-4 1992 This increased expression of P-gp was associated with decreased intracellular retention of doxorubicin, which could be restored by compounds such as verapamil and cyclosporin; doxorubicin (and also vincristine) was more cytotoxic to early than to late cultures. Cyclosporine 163-174 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 29-33 33405191-3 2021 METHOD: P-gp modulation in rats was performed by using P-gp inducer (150 mg/kg rifampicin) and P-gp inhibitor (10 mg/kg cyclosporine A) for 14 days prior to be infected with Helicobacter pylori (H. pylori). Cyclosporine 120-134 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 8-12 32653591-9 2020 Moreover, the decreased Clop-AM level in T2DM rats was eliminated by the pretreatment of cyclosporin A, a P-gp inhibitor. Cyclosporine 89-102 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 106-110 7912496-4 1994 Both cyclosporin A and rhodamine inhibited photoaffinity labeling of immunoprecipitated P-glycoprotein with azidopine, indicating binding to hepatic P-glycoprotein. Cyclosporine 5-18 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 88-102 7912496-4 1994 Both cyclosporin A and rhodamine inhibited photoaffinity labeling of immunoprecipitated P-glycoprotein with azidopine, indicating binding to hepatic P-glycoprotein. Cyclosporine 5-18 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 149-163 7905714-0 1994 Interaction of rat kidney P-glycoprotein with a urinary component and various drugs including cyclosporin A. Cyclosporine 94-107 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 26-40 7905714-7 1994 Of the drugs tested, the immunosuppressant drug, cyclosporin A, interacted with kidney P-glycoprotein with the highest affinity (K0.5 = 50 nM). Cyclosporine 49-62 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 87-101 7905714-11 1994 A hypothesis of drug-induced nephrotoxicity based on the interaction of various compounds like cyclosporin A with P-glycoprotein is presented. Cyclosporine 95-108 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 114-128 32393425-4 2020 At present, most studies focused on the inhibition of bile excretion by cyclosporin A through the transporters MRP2 and MDR1 and its effect the irinotecan treatment in vivo. Cyclosporine 72-85 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 120-124 30663770-13 2019 CONCLUSIONS: Multiple doses of BG decreased the oral bioavailability of CsA in rats significantly, which may be mainly attributable to inhibition of absorption of CsA in intestine and induction of P-gp. Cyclosporine 72-75 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 197-201 29703381-0 2018 Activation of P-glycoprotein and CYP 3A by Coptidis Rhizoma in vivo: Using cyclosporine as a probe substrate in rats. Cyclosporine 75-87 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 14-28 29703381-3 2018 Cyclosporine (CSP), an important immunosuppressant with narrow therapeutic window, is employed as a probe substrate of P-glycoprotein (P-gp) and CYP3A4 in order to investigate the in vivo modulation effect of CR on P-gp and CYP3A4. Cyclosporine 0-12 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 119-133 29703381-3 2018 Cyclosporine (CSP), an important immunosuppressant with narrow therapeutic window, is employed as a probe substrate of P-glycoprotein (P-gp) and CYP3A4 in order to investigate the in vivo modulation effect of CR on P-gp and CYP3A4. Cyclosporine 0-12 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 135-139 29703381-3 2018 Cyclosporine (CSP), an important immunosuppressant with narrow therapeutic window, is employed as a probe substrate of P-glycoprotein (P-gp) and CYP3A4 in order to investigate the in vivo modulation effect of CR on P-gp and CYP3A4. Cyclosporine 0-12 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 215-219 29703381-3 2018 Cyclosporine (CSP), an important immunosuppressant with narrow therapeutic window, is employed as a probe substrate of P-glycoprotein (P-gp) and CYP3A4 in order to investigate the in vivo modulation effect of CR on P-gp and CYP3A4. Cyclosporine 14-17 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 119-133 29703381-3 2018 Cyclosporine (CSP), an important immunosuppressant with narrow therapeutic window, is employed as a probe substrate of P-glycoprotein (P-gp) and CYP3A4 in order to investigate the in vivo modulation effect of CR on P-gp and CYP3A4. Cyclosporine 14-17 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 135-139 29703381-3 2018 Cyclosporine (CSP), an important immunosuppressant with narrow therapeutic window, is employed as a probe substrate of P-glycoprotein (P-gp) and CYP3A4 in order to investigate the in vivo modulation effect of CR on P-gp and CYP3A4. Cyclosporine 14-17 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 215-219 28917111-11 2017 PET imaging showed that [11C]PF-3274167 uptake in rat brain was very low in basal conditions but increased significantly after the administration of ciclosporin, suggesting that it is a substrate of the P-gp. Cyclosporine 149-160 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 203-207 28709912-6 2017 Inhibition of P-gp by oral pre-treatment with cyclosporine A increased the bioavailability of the P-gp substrates (ampicillin and ranitidine) in males and females (p<0.05), and to a greater extent in males, but had no influence on the bioavailability of metformin in either male or female rats. Cyclosporine 46-60 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 14-18 28709912-6 2017 Inhibition of P-gp by oral pre-treatment with cyclosporine A increased the bioavailability of the P-gp substrates (ampicillin and ranitidine) in males and females (p<0.05), and to a greater extent in males, but had no influence on the bioavailability of metformin in either male or female rats. Cyclosporine 46-60 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 98-102 25785492-2 2015 CsA, a hydrophobic peptide that is also a substrate for P-glycoprotein, is a well-known immunosuppressive agent. Cyclosporine 0-3 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 56-70 28009901-0 2017 Aloe activated P-glycoprotein and CYP 3A: a study on the serum kinetics of aloe and its interaction with cyclosporine in rats. Cyclosporine 105-117 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 15-29 28009901-3 2017 Cyclosporine (CSP), an immunosuppressant with a narrow therapeutic window, is a probe substrate of P-glycoprotein (P-gp), an efflux pump, and CYP 3A4. Cyclosporine 0-12 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 99-113 28009901-3 2017 Cyclosporine (CSP), an immunosuppressant with a narrow therapeutic window, is a probe substrate of P-glycoprotein (P-gp), an efflux pump, and CYP 3A4. Cyclosporine 0-12 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 115-119 28009901-3 2017 Cyclosporine (CSP), an immunosuppressant with a narrow therapeutic window, is a probe substrate of P-glycoprotein (P-gp), an efflux pump, and CYP 3A4. Cyclosporine 14-17 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 99-113 28009901-3 2017 Cyclosporine (CSP), an immunosuppressant with a narrow therapeutic window, is a probe substrate of P-glycoprotein (P-gp), an efflux pump, and CYP 3A4. Cyclosporine 14-17 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 115-119 27287416-9 2016 Furthermore, the therapeutic enhancement by tariquidar was compared to that of the less specific and less potent Pgp inhibitor cyclosporine A. Cyclosporine 127-141 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 113-116 27000241-4 2016 Tetrandrine (0.1, 0.3, 1 muM) or cyclosporine A (0.1, 0.3, 1 muM) had non-competitively inhibitory manner on Z-guggulsterone-stimulated P-glycoprotein ATPase activity, suggesting that Z-guggulsterone might have unique binding site or regulating site on P-glycoprotein. Cyclosporine 33-47 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 136-150 27000241-4 2016 Tetrandrine (0.1, 0.3, 1 muM) or cyclosporine A (0.1, 0.3, 1 muM) had non-competitively inhibitory manner on Z-guggulsterone-stimulated P-glycoprotein ATPase activity, suggesting that Z-guggulsterone might have unique binding site or regulating site on P-glycoprotein. Cyclosporine 33-47 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 253-267 26972494-8 2016 Furthermore, both cyclosporine A (P-glycoprotein inhibitor) and MK-571 (MRP-2 inhibitor) significantly increased the cellular uptake and transport of (+)-catechin and puerarin. Cyclosporine 18-32 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 34-48 27627555-0 2016 The Effect of P-Glycoprotein Inhibition and Activation on the Absorption and Serum Levels of Cyclosporine and Tacrolimus in Rats. Cyclosporine 93-105 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 14-28 27627555-1 2016 BACKGROUND: Permeability glycoprotein (P-glycoprotein or P-gp) plays an important role in the intestinal absorption of the immunosuppressive agents: cyclosporine and tacrolimus. Cyclosporine 149-161 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 39-53 26031900-3 2016 As only a high intestinal first-pass effect of VR was found, that is, there existed a low bioavailability of VR (2.40%), inhibitors of P-glycoprotein (P-gp) and cytochrome P450 3A (CYP3A), including verapamil, cyclosporin A and midazolam, and absorption enhancers, including bile salts and borneol, combined with VR, were instilled into duodenum to evaluate the effects on bioavailability of VR. Cyclosporine 210-223 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 135-149 25947324-2 2015 We, therefore, studied if a potent P-gp and MRP modulator, cyclosporin A (CysA), can modulate the MTX concentration in the rat brain. Cyclosporine 59-72 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 35-39 25947324-2 2015 We, therefore, studied if a potent P-gp and MRP modulator, cyclosporin A (CysA), can modulate the MTX concentration in the rat brain. Cyclosporine 74-78 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 35-39 25310383-2 2014 However, alisporivir, cyclosporin A, and most other cyclosporins are potent inhibitors of OATP1B1, MRP2, MDR1, and other important drug transporters. Cyclosporine 22-35 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 105-109 26329549-4 2015 The first finding is that the oral bioavailability of cyclosporine A (CsA), which is an immunosuppressant, was decreased by increased first-pass metabolism due to elevated CYP3A and P-glycoprotein (P-gp) specifically in the upper small intestine after liver I/R. Cyclosporine 54-68 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 182-196 26329549-4 2015 The first finding is that the oral bioavailability of cyclosporine A (CsA), which is an immunosuppressant, was decreased by increased first-pass metabolism due to elevated CYP3A and P-glycoprotein (P-gp) specifically in the upper small intestine after liver I/R. Cyclosporine 54-68 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 198-202 26329549-4 2015 The first finding is that the oral bioavailability of cyclosporine A (CsA), which is an immunosuppressant, was decreased by increased first-pass metabolism due to elevated CYP3A and P-glycoprotein (P-gp) specifically in the upper small intestine after liver I/R. Cyclosporine 70-73 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 182-196 26329549-4 2015 The first finding is that the oral bioavailability of cyclosporine A (CsA), which is an immunosuppressant, was decreased by increased first-pass metabolism due to elevated CYP3A and P-glycoprotein (P-gp) specifically in the upper small intestine after liver I/R. Cyclosporine 70-73 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 198-202 25747979-7 2015 P-gp inhibition by cyclosporine A (CsA) increased absorptive permeability of morin 2.4-fold but decreased the efflux of morin by 52%, which was consistent with increased plasma concentration of morin in the pretreatment of CsA in rats. Cyclosporine 19-33 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 0-4 25747979-7 2015 P-gp inhibition by cyclosporine A (CsA) increased absorptive permeability of morin 2.4-fold but decreased the efflux of morin by 52%, which was consistent with increased plasma concentration of morin in the pretreatment of CsA in rats. Cyclosporine 35-38 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 0-4 25747979-7 2015 P-gp inhibition by cyclosporine A (CsA) increased absorptive permeability of morin 2.4-fold but decreased the efflux of morin by 52%, which was consistent with increased plasma concentration of morin in the pretreatment of CsA in rats. Cyclosporine 223-226 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 0-4 24502637-9 2014 The findings of these experiments suggested that in hyperlipidemia the expression and (or) the functional activity of P-glycoprotein was diminished, leading to greater hepatic and renal uptake of cyclosporine A, and renal cellular toxicity. Cyclosporine 196-210 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 118-132 24555822-9 2014 The P-gp inhibitors cyclosporine and elacridar (i.e. GF120918A) markedly enhanced SNX-2112 absorption in all four intestinal segments (i.e. duodenum, jejunum, ileum and colon) and the fold change ranged from 3.1 to 14.1. Cyclosporine 20-32 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 4-8 24090809-4 2013 Kinetic studies on ATPase activity showed the effects of Tetrandrine (Tet) on CJY-stimulated, CsA on CJY-stimulated, and CsA on Tet-stimulated P-gp ATPase activity were all non-competitive inhibition, indicating that these substrates can simultaneously but independently bind to diverse sites on P-gp. Cyclosporine 121-124 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 143-147 24013073-0 2013 Capsaicin pretreatment increased the bioavailability of cyclosporin in rats: involvement of P-glycoprotein and CYP 3A inhibition. Cyclosporine 56-67 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 92-106 24090809-4 2013 Kinetic studies on ATPase activity showed the effects of Tetrandrine (Tet) on CJY-stimulated, CsA on CJY-stimulated, and CsA on Tet-stimulated P-gp ATPase activity were all non-competitive inhibition, indicating that these substrates can simultaneously but independently bind to diverse sites on P-gp. Cyclosporine 121-124 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 296-300 22749977-2 2012 Although oral bioavailability of cyclosporine A (CsA) was decreased by increased first-pass metabolism through CYP3A and P-glycoprotein (P-gp) specifically in the upper small intestine after liver I/R, the mechanism responsible for them remained to be clarified. Cyclosporine 33-47 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 121-135 23791640-4 2013 In another experiment, rhodamine 123 was used to quantify the biliary canalicular transporter P-glycoprotein (P-gp, Abcb1a/b) with cyclosporin A as an inhibitor of P-gp activity. Cyclosporine 131-144 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 94-108 23791640-4 2013 In another experiment, rhodamine 123 was used to quantify the biliary canalicular transporter P-glycoprotein (P-gp, Abcb1a/b) with cyclosporin A as an inhibitor of P-gp activity. Cyclosporine 131-144 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 110-114 23791640-4 2013 In another experiment, rhodamine 123 was used to quantify the biliary canalicular transporter P-glycoprotein (P-gp, Abcb1a/b) with cyclosporin A as an inhibitor of P-gp activity. Cyclosporine 131-144 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 164-168 22749977-2 2012 Although oral bioavailability of cyclosporine A (CsA) was decreased by increased first-pass metabolism through CYP3A and P-glycoprotein (P-gp) specifically in the upper small intestine after liver I/R, the mechanism responsible for them remained to be clarified. Cyclosporine 33-47 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 137-141 22749977-2 2012 Although oral bioavailability of cyclosporine A (CsA) was decreased by increased first-pass metabolism through CYP3A and P-glycoprotein (P-gp) specifically in the upper small intestine after liver I/R, the mechanism responsible for them remained to be clarified. Cyclosporine 49-52 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 121-135 22749977-2 2012 Although oral bioavailability of cyclosporine A (CsA) was decreased by increased first-pass metabolism through CYP3A and P-glycoprotein (P-gp) specifically in the upper small intestine after liver I/R, the mechanism responsible for them remained to be clarified. Cyclosporine 49-52 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 137-141 22749977-3 2012 In the present study, the effect of Trolox (an alpha-tocopherol analogue) on the decreased oral absorption of CsA through elevated intestinal CYP3A and P-gp after liver I/R and their regulations were investigated. Cyclosporine 110-113 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 152-156 22749977-9 2012 These results demonstrate that Trolox ameliorates the decreased oral absorption of CsA through elevated intestinal CYP3A and P-gp by preventing oxidative stress, where the biliary lithocholic acid may be responsible for the elevated transcription of CYP3A specifically in the upper small intestine after liver I/R. Cyclosporine 83-86 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 125-129 21869731-13 2012 Furthermore, CsA increased Mdr1 protein abundance to a greater extent in Mrp2-/- than in wild-type kidneys. Cyclosporine 13-16 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 27-31 21869731-15 2012 The high Mdr1 abundance may at least in part prevent exaggerated CsA accumulation in Mrp2-/- kidneys. Cyclosporine 65-68 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 9-13 22361031-1 2012 Co-administration of P-glycoprotein (P-gp) inhibitors such as cyclosporine A (CyA) and its analogue valspodar with doxorubicin (DOX) can result in diminished clearance of DOX, leading to accentuated toxicity. Cyclosporine 62-76 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 21-35 22361031-1 2012 Co-administration of P-glycoprotein (P-gp) inhibitors such as cyclosporine A (CyA) and its analogue valspodar with doxorubicin (DOX) can result in diminished clearance of DOX, leading to accentuated toxicity. Cyclosporine 62-76 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 37-41 22169469-9 2012 These results demonstrated that the CsA decreased the efflux of spinosin through the inhibition of P-glycoprotein (P-gp) efflux transporter and it might be used as a group of P-gp substrate. Cyclosporine 36-39 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 99-113 22764568-5 2012 The pretreatment with cyclosporine A, a P-gp inhibitor, greatly increased the intestinal absorption of quinidine given at a dose of 0.1 mg/kg. Cyclosporine 22-36 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 40-44 22079035-9 2012 Cyclosporin A studies indicate that the fast liver and kidney clearance kinetics is mediated by P-glycoprotein (Pgp), supporting the potential interest of this radiotracer for imaging Pgp function associated with multidrug-resistant tumours. Cyclosporine 0-13 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 96-110 22316009-0 2012 P-glycoprotein-based loperamide-cyclosporine drug interaction at the rat blood-brain barrier: prediction from in vitro studies and extrapolation to humans. Cyclosporine 32-44 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 0-14 22079035-9 2012 Cyclosporin A studies indicate that the fast liver and kidney clearance kinetics is mediated by P-glycoprotein (Pgp), supporting the potential interest of this radiotracer for imaging Pgp function associated with multidrug-resistant tumours. Cyclosporine 0-13 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 112-115 22079035-9 2012 Cyclosporin A studies indicate that the fast liver and kidney clearance kinetics is mediated by P-glycoprotein (Pgp), supporting the potential interest of this radiotracer for imaging Pgp function associated with multidrug-resistant tumours. Cyclosporine 0-13 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 184-187 22115032-8 2011 Protein band of 170 kDa manifested the existence of P-gp in the rBMECs, and the findings of cyclosporin A-sensitive decrease of Rho123 efflux confirmed the presence of P-gp activity. Cyclosporine 92-105 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 168-172 21737631-3 2011 MATERIALS AND METHODS: Single-pass antegrade ILP (A-ILP) was performed with doxorubicin in rats bearing a pulmonary sarcoma nodule which were either untreated or received P-gp inhibitors cyclosporin, valspodar or the vehicle, Cremophor , only. Cyclosporine 187-198 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 171-175 21737631-8 2011 CONCLUSION: P-gp modulation with cyclosporin or valspodar fails to increase the tumor uptake of doxorubin administered by A-ILP. Cyclosporine 33-44 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 12-16 19819100-1 2009 Nifedipine (NFP) is an anti-hypersensitive drug and a well-known substrate of cytochrome P450 3A4 (CYP3A4), while cyclosporine (CSP) is a potent p-glycoprotein (P-gp) inhibitor. Cyclosporine 114-126 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 145-159 21421030-4 2011 Co-administration of Danshen did not affect the plasma concentration profiles and pharmacokinetic parameters of docetaxel and clopidogrel, whereas cyclosporine A, a P-gp and CYP3A inhibitor, significantly influenced the pharmacokinetics of co-administered docetaxel and clopidogrel. Cyclosporine 147-161 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 165-169 19819100-1 2009 Nifedipine (NFP) is an anti-hypersensitive drug and a well-known substrate of cytochrome P450 3A4 (CYP3A4), while cyclosporine (CSP) is a potent p-glycoprotein (P-gp) inhibitor. Cyclosporine 114-126 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 161-165 19819100-1 2009 Nifedipine (NFP) is an anti-hypersensitive drug and a well-known substrate of cytochrome P450 3A4 (CYP3A4), while cyclosporine (CSP) is a potent p-glycoprotein (P-gp) inhibitor. Cyclosporine 128-131 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 145-159 19819100-1 2009 Nifedipine (NFP) is an anti-hypersensitive drug and a well-known substrate of cytochrome P450 3A4 (CYP3A4), while cyclosporine (CSP) is a potent p-glycoprotein (P-gp) inhibitor. Cyclosporine 128-131 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 161-165 18985346-3 2009 The function of Pgp can be blocked with cyclosporin A. Cyclosporine 40-53 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 16-19 18855917-3 2009 The activities of P-gp in these models were characterized using a known substrate (quinidine) and known inhibitors [cyclosporine A (CyA), GF-120918, PSC-833] of P-gp. Cyclosporine 116-130 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 18-22 18855917-3 2009 The activities of P-gp in these models were characterized using a known substrate (quinidine) and known inhibitors [cyclosporine A (CyA), GF-120918, PSC-833] of P-gp. Cyclosporine 116-130 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 161-165 19951574-15 2009 After co-incubation with cyclosporine A (CsA), specific inhibitor to P-glycoprotein, the second phase of insulin secretion was reduced significantly while the first phase was not influenced. Cyclosporine 25-39 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 69-83 19951574-15 2009 After co-incubation with cyclosporine A (CsA), specific inhibitor to P-glycoprotein, the second phase of insulin secretion was reduced significantly while the first phase was not influenced. Cyclosporine 41-44 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 69-83 19746191-9 2009 Pretreatment with Cyclosporin A raised brain uptake indicating that [(123)I]-7 is transported by P-glycoprotein (P-gp) pumps. Cyclosporine 18-31 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 97-111 19746191-9 2009 Pretreatment with Cyclosporin A raised brain uptake indicating that [(123)I]-7 is transported by P-glycoprotein (P-gp) pumps. Cyclosporine 18-31 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 113-117 19111511-4 2009 as control group and the treated-group rats were co-administered with kadsurenone and CsA; P-gp inhibitor. Cyclosporine 86-89 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 91-95 19013229-7 2009 Activity of efflux transporters was confirmed in both placental primocultures and cryopreserved trophoblasts by an approximately 60% inhibition with cyclosporin A and valspodar for P-gp and 55% with elacridar for bcrp. Cyclosporine 149-162 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 181-185 18842703-8 2009 Our study clearly demonstrates for the first time that liver I/R decreases the oral bioavailability of CsA and that this is attributable principally to increased first-pass metabolism mediated by CYP3A and P-gp in the upper small intestine. Cyclosporine 103-106 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 206-210 18604533-0 2008 Cyclosporine, a P-glycoprotein modulator, increases [18F]MPPF uptake in rat brain and peripheral tissues: microPET and ex vivo studies. Cyclosporine 0-12 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 16-30 18604533-1 2008 PURPOSE: Pretreatment with cyclosporine, a P-glycoprotein (P-gp) modulator increases brain uptake of 4-(2"-methoxyphenyl)-1-[2"-(N-2"-pyridinyl)-p-[(18)F]fluorobenzamido]ethylpiperazine ([(18)F]MPPF) for binding to hydroxytryptamine(1A) (5-HT(1A)) receptors. Cyclosporine 27-39 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 43-57 18604533-1 2008 PURPOSE: Pretreatment with cyclosporine, a P-glycoprotein (P-gp) modulator increases brain uptake of 4-(2"-methoxyphenyl)-1-[2"-(N-2"-pyridinyl)-p-[(18)F]fluorobenzamido]ethylpiperazine ([(18)F]MPPF) for binding to hydroxytryptamine(1A) (5-HT(1A)) receptors. Cyclosporine 27-39 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 59-63 18485890-2 2008 P-gp overexpression in MDCK-MDR cells was correlated with enhanced cell migration whereas treatment with P-gp inhibitors CsA or PSC833 reduced it. Cyclosporine 121-124 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 105-109 18817631-1 2008 AIM: To evaluate the effects of cyclosporin A and itraconazole, which were used as inhibitors of P-glycoprotein (P-gp) and/or cytochrome P450 (CYP) 3A4 on the pharmacokinetics of atorvastatin in rats. Cyclosporine 32-45 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 97-111 18725544-1 2008 This study examined the contribution of changes in regulation of intestinal and hepatic cytochrome P450 3A (CYP3A) and multidrug resistance transporter 1 (Mdr1) to absorption of cyclosporine A (CsA) in a rat nephrosis model. Cyclosporine 178-192 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 155-159 19356088-1 2008 Cyclosporin A (CsA) is a P-glycoprotein (P-gp) inhibitor clinically used as an immunosuppressant. Cyclosporine 0-13 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 25-39 19356088-1 2008 Cyclosporin A (CsA) is a P-glycoprotein (P-gp) inhibitor clinically used as an immunosuppressant. Cyclosporine 0-13 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 41-45 18424002-9 2008 Pretreatment of P-glycoprotein inhibitors verapamil or cyclosporin A significantly increased the brain remaining percentage of [(125)I]hAbeta (1-40). Cyclosporine 55-68 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 16-30 19356088-1 2008 Cyclosporin A (CsA) is a P-glycoprotein (P-gp) inhibitor clinically used as an immunosuppressant. Cyclosporine 15-18 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 25-39 19356088-1 2008 Cyclosporin A (CsA) is a P-glycoprotein (P-gp) inhibitor clinically used as an immunosuppressant. Cyclosporine 15-18 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 41-45 18482683-5 2008 METHODS: In control rats and in rats treated with the Pgp modulator cyclosporin A (CsA), cerebral accumulation of radiolabeled [(11)C]celecoxib was investigated by ex vivo biodistribution and micro-positron emission tomography imaging. Cyclosporine 68-81 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 54-57 18482683-5 2008 METHODS: In control rats and in rats treated with the Pgp modulator cyclosporin A (CsA), cerebral accumulation of radiolabeled [(11)C]celecoxib was investigated by ex vivo biodistribution and micro-positron emission tomography imaging. Cyclosporine 83-86 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 54-57 18482683-6 2008 In addition, the effect of unlabeled celecoxib and CsA (positive control) on the cerebral uptake of the Pgp substrate [(11)C]verapamil was studied. Cyclosporine 51-54 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 104-107 17664251-1 2007 The objective of this study was to investigate the transport kinetics of cyclosporin A, a well known substrate for P-glycoprotein (P-gp), across the blood-brain barrier (BBB), and the expression of the transporter in the brain of streptozotocin-induced diabetic rats. Cyclosporine 73-86 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 115-129 18540481-2 2008 The second objective was to assess the quantitative contribution of P-glycoprotein (P-gp)-mediated efflux in limiting the oral bioavailability of CsA using erythromycin (Ery, CAS 114-07-8) as an inhibitor of P-gp efflux transporter. Cyclosporine 146-149 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 68-82 18540481-2 2008 The second objective was to assess the quantitative contribution of P-glycoprotein (P-gp)-mediated efflux in limiting the oral bioavailability of CsA using erythromycin (Ery, CAS 114-07-8) as an inhibitor of P-gp efflux transporter. Cyclosporine 146-149 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 84-88 17664251-1 2007 The objective of this study was to investigate the transport kinetics of cyclosporin A, a well known substrate for P-glycoprotein (P-gp), across the blood-brain barrier (BBB), and the expression of the transporter in the brain of streptozotocin-induced diabetic rats. Cyclosporine 73-86 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 131-135 17117422-0 2007 Effect of a P-glycoprotein inhibitor, Cyclosporin A, on the disposition in rodent brain and blood of the 5-HT1A receptor radioligand, [11C](R)-(-)-RWAY. Cyclosporine 38-51 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 12-26 17845805-11 2007 Co-administration of CsA increased PB levels in brain and enhanced anticonvulsive effects of PB by inhibiting P-GP function. Cyclosporine 21-24 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 110-114 17609666-4 2007 To elucidate whether radiation therapy reduces P-gp expression and function in the brain, right hemispheres of rats were irradiated with single doses of 2-25 Gy followed by 10 mg kg(-1) of the P-gp substrate cyclosporine A (CsA) intravenously (i.v. Cyclosporine 208-222 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 193-197 19093450-5 2007 Cyclosporine, a P-glycoprotein/MRP2 inhibitor, significantly suppressed the efflux transport of andrographolide in distal region of intestine, whereas probenecid, an MRP inhibitor, showed no significant effect in both proximal and distal regions of intestine. Cyclosporine 0-12 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 16-30 17207946-9 2007 Significant permeability enhancement of SQV across rat jejunum was observed in the presence of cyclosporine 10 microM (P-gp inhibitor). Cyclosporine 95-107 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 119-123 16545584-12 2006 The cells demonstrated P-glycoprotein-mediated function by directional transport of dexamethasone, ritonavir, and vinblastine in a transwell assay that was inhibited in the presence of cyclosporin A, verapamil, or quinidine. Cyclosporine 185-198 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 23-37 17365275-2 2007 P-gp inhibitors, such as cyclosporin A, quinidine and verapamil, enhanced the apparent brain uptake of [3H]BNP by 1.5-fold. Cyclosporine 25-38 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 0-4 17015956-5 2006 In in vitro monolayer efflux assays, compound 3 was found to be a substrate for the P-glycoprotein (P-gp) efflux pump, but pretreatment of rats with the potent P-gp inhibitor, cyclosporine A, did not have any significant influence on the cerebral uptake of [11C]3. Cyclosporine 176-190 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 84-98 17015956-5 2006 In in vitro monolayer efflux assays, compound 3 was found to be a substrate for the P-glycoprotein (P-gp) efflux pump, but pretreatment of rats with the potent P-gp inhibitor, cyclosporine A, did not have any significant influence on the cerebral uptake of [11C]3. Cyclosporine 176-190 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 100-104 17015956-5 2006 In in vitro monolayer efflux assays, compound 3 was found to be a substrate for the P-glycoprotein (P-gp) efflux pump, but pretreatment of rats with the potent P-gp inhibitor, cyclosporine A, did not have any significant influence on the cerebral uptake of [11C]3. Cyclosporine 176-190 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 160-164 16793245-2 2006 Cyclosporin A (CsA) as an essential immunosuppressive drug has potentially cholestatic adverse effects on the liver, but increases the expression of mdr1. Cyclosporine 0-13 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 149-153 16793245-2 2006 Cyclosporin A (CsA) as an essential immunosuppressive drug has potentially cholestatic adverse effects on the liver, but increases the expression of mdr1. Cyclosporine 15-18 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 149-153 16793245-11 2006 The similar effects of V and CsA on BA transport and metabolism can be explained by mdr1 mediated disturbances of cellular ATP transport rather than by inhibition of individual BA transporters. Cyclosporine 29-32 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 84-88 16252067-0 2006 Cyclosporine A (CsA) affects the pharmacodynamics and pharmacokinetics of the atypical antipsychotic amisulpride probably via inhibition of P-glycoprotein (P-gp). Cyclosporine 0-14 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 140-154 16252067-0 2006 Cyclosporine A (CsA) affects the pharmacodynamics and pharmacokinetics of the atypical antipsychotic amisulpride probably via inhibition of P-glycoprotein (P-gp). Cyclosporine 0-14 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 156-160 16252067-0 2006 Cyclosporine A (CsA) affects the pharmacodynamics and pharmacokinetics of the atypical antipsychotic amisulpride probably via inhibition of P-glycoprotein (P-gp). Cyclosporine 16-19 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 140-154 16252067-0 2006 Cyclosporine A (CsA) affects the pharmacodynamics and pharmacokinetics of the atypical antipsychotic amisulpride probably via inhibition of P-glycoprotein (P-gp). Cyclosporine 16-19 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 156-160 16252067-7 2006 These results pointed to a pharmacokinetic drug interaction between CsA and amisulpride most likely caused by inhibition of P-gp. Cyclosporine 68-71 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 124-128 16805961-4 2006 Because both drugs are transported via P-glycoprotein and breast cancer resistance protein and metabolized by cytochrome P450 3A2, the interaction of imatinib mesilate with these proteins may be responsible for the increased intestinal absorption of ciclosporin in rats. Cyclosporine 250-261 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 39-53 16857389-0 2006 Duration and degree of cyclosporin induced P-glycoprotein inhibition in the rat blood-brain barrier can be studied with PET. Cyclosporine 23-34 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 43-57 16857389-5 2006 The P-gp modulator cyclosporin A (CsA) (3, 10 and 25 mg/kg) was administered as a short bolus injection 30 min after the start of the [(11)C]verapamil infusion. Cyclosporine 19-32 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 4-8 16857389-7 2006 The CsA blood concentrations were used as input to model P-gp inhibition. Cyclosporine 4-7 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 57-61 16857389-10 2006 A model in which CsA inhibited P-gp by decreasing the transport of [(11)C]verapamil out from the brain resulted in the best fit. Cyclosporine 17-20 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 31-35 16857389-11 2006 Our data suggest that it is not the CsA concentration in blood, but rather the CsA concentration in an effect compartment, probably the endothelial cells of the blood-brain barrier that is responsible for the inhibition of P-gp. Cyclosporine 79-82 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 223-227 16415090-11 2006 This is the first time that an in vivo CsA EC(50) of P-gp inhibition at the rat BBB has been determined and the magnitude of such inhibition was compared between the rat and the human BBB at the same blood CsA concentration. Cyclosporine 39-42 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 53-57 16457995-3 2006 Intestinal absorption of tacrolimus itself was as extensive as other P-gp modulators such as cyclosporine and verapamil. Cyclosporine 93-105 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 69-73 16457995-4 2006 While cyclosporine and verapamil significantly increased the absorption of methylprednisolone and vinblastine through potent inhibition of intestinal P-gp, tacrolimus failed to achieve this. Cyclosporine 6-18 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 150-154 16457995-8 2006 It was considered that the extensive absorption of cyclosporine and verapamil was closely associated with their potent ability to inhibit intestinal P-gp. Cyclosporine 51-63 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 149-153 16353156-6 2006 Cyclosporin A, a competitive inhibitor of Pgp, increased the intracellular accumulation of DOX and reduced the resistance to it. Cyclosporine 0-13 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 42-45 15858844-1 2005 Recently, we found that potent P-glycoprotein (P-gp) inhibitors, such as verapamil and cyclosporin A, markedly modulated the pharmacokinetics of digoxin in rats, whereas they did not affect beta-methyldigoxin pharmacokinetics significantly. Cyclosporine 87-100 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 31-45 15951832-6 2005 Cellular [(11)C]carvedilol accumulation in GLC(4), GLC(4)/P-gp, and GLC(4)/Adr cells increased three-fold in the GLC(4)/P-gp cells after pretreatment with cyclosporin A (CsA) whereas no effect of MK571 could be determined in the GLC(4)/Adr cells. Cyclosporine 155-168 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 120-124 15951832-6 2005 Cellular [(11)C]carvedilol accumulation in GLC(4), GLC(4)/P-gp, and GLC(4)/Adr cells increased three-fold in the GLC(4)/P-gp cells after pretreatment with cyclosporin A (CsA) whereas no effect of MK571 could be determined in the GLC(4)/Adr cells. Cyclosporine 170-173 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 120-124 15951832-10 2005 In vivo PET experiments were performed with and without P-gp modulation by CsA. Cyclosporine 75-78 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 56-60 16085598-8 2005 To demonstrate the influence of P-glycoprotein on cerebral uptake of (11)C-GR218231, the efflux pump was modulated with 50 mg/kg cyclosporine A. Cyclosporine 129-143 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 32-46 16085598-13 2005 Modulation of P-glycoprotein with cyclosporine A caused a 12-fold higher (11)C-GR218231 uptake in the brain, indicating that the low cerebral tracer uptake was caused by the P-glycoprotein efflux pump in the blood-brain barrier. Cyclosporine 34-48 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 14-28 16085598-13 2005 Modulation of P-glycoprotein with cyclosporine A caused a 12-fold higher (11)C-GR218231 uptake in the brain, indicating that the low cerebral tracer uptake was caused by the P-glycoprotein efflux pump in the blood-brain barrier. Cyclosporine 34-48 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 174-188 16476567-2 2006 CsA is reported to competitively inhibit the transport of the substrates of the bile salt export pump (Bsep), multidrug resistance protein 2 (Mrp2) and P-glycoprotein (P-gp) in the canalicular membrane vesicles. Cyclosporine 0-3 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 152-166 16476567-2 2006 CsA is reported to competitively inhibit the transport of the substrates of the bile salt export pump (Bsep), multidrug resistance protein 2 (Mrp2) and P-glycoprotein (P-gp) in the canalicular membrane vesicles. Cyclosporine 0-3 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 168-172 16476567-4 2006 Therefore, in the present study, the acute effect of CsA on the biliary excretion of the substrates of Bsep, Mrp2 and P-gp was examined under the same condition. Cyclosporine 53-56 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 118-122 16476567-8 2006 In conclusion, CsA may competitively inhibit biliary excretion of substrates of Bsep, Mrp2 and P-gp also in vivo, and CsA is considered to inhibit bile acid-dependent bile flow by the competitive inhibition of the canalicular transport of bile acids by Bsep. Cyclosporine 15-18 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 95-99 15858844-1 2005 Recently, we found that potent P-glycoprotein (P-gp) inhibitors, such as verapamil and cyclosporin A, markedly modulated the pharmacokinetics of digoxin in rats, whereas they did not affect beta-methyldigoxin pharmacokinetics significantly. Cyclosporine 87-100 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 47-51 15624117-4 2005 Half the rats were treated with the P-glycoprotein inhibitor cyclosporine A (CsA) (200 mg/kg) 2 h prior to NT administration, and the other half served as a control group. Cyclosporine 61-75 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 36-50 15910387-1 2005 We encountered two cases of pediatric living-related liver transplant recipients who showed increases in blood concentration of cyclosporine or tacrolimus, a dual substrate for cytochrome P450 (CYP) 3A and P-glycoprotein (P-gp), during a diarrheal episode. Cyclosporine 128-140 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 206-220 15910387-1 2005 We encountered two cases of pediatric living-related liver transplant recipients who showed increases in blood concentration of cyclosporine or tacrolimus, a dual substrate for cytochrome P450 (CYP) 3A and P-glycoprotein (P-gp), during a diarrheal episode. Cyclosporine 128-140 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 222-226 15910387-8 2005 These findings suggest that the suppression of CYP3A and P-gp activities may be involved in the mechanism of elevated blood concentrations of cyclosporine and tacrolimus during enteritis-induced diarrhea. Cyclosporine 142-154 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 57-61 15909533-12 2005 In addition, the AUC of ranitidine in bile decreased in the treatment of cyclosporine or quinidine, which suggests that the hepatobiliary excretion of ranitidine was partially regulated by P-glycoprotein or organic cation transporter. Cyclosporine 73-85 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 189-203 15624117-8 2005 These results suggest that inhibition of P-gp by CsA increases the accumulation of NT in the brain. Cyclosporine 49-52 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 41-45 15684491-0 2005 In vivo effects of cyclosporin A and ketoconazole on the pharmacokinetics of representative substrates for P-glycoprotein and cytochrome P450 (CYP) 3A in rats. Cyclosporine 19-32 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 107-121 15684491-1 2005 In this study, the in vivo effects of cyclosporin A (CsA) and ketoconazole (KCZ), which are used as inhibitors of P-glycoprotein (Pgp) and cytochrome P450 (CYP) 3A, respectively, on the pharmacokinetics of rhodamine 123 (Rho123), nelfinavir (NFV) and erythromycin (EM) were evaluated in rats. Cyclosporine 38-51 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 114-128 15684491-1 2005 In this study, the in vivo effects of cyclosporin A (CsA) and ketoconazole (KCZ), which are used as inhibitors of P-glycoprotein (Pgp) and cytochrome P450 (CYP) 3A, respectively, on the pharmacokinetics of rhodamine 123 (Rho123), nelfinavir (NFV) and erythromycin (EM) were evaluated in rats. Cyclosporine 53-56 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 114-128 15684491-1 2005 In this study, the in vivo effects of cyclosporin A (CsA) and ketoconazole (KCZ), which are used as inhibitors of P-glycoprotein (Pgp) and cytochrome P450 (CYP) 3A, respectively, on the pharmacokinetics of rhodamine 123 (Rho123), nelfinavir (NFV) and erythromycin (EM) were evaluated in rats. Cyclosporine 38-51 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 130-133 15684491-1 2005 In this study, the in vivo effects of cyclosporin A (CsA) and ketoconazole (KCZ), which are used as inhibitors of P-glycoprotein (Pgp) and cytochrome P450 (CYP) 3A, respectively, on the pharmacokinetics of rhodamine 123 (Rho123), nelfinavir (NFV) and erythromycin (EM) were evaluated in rats. Cyclosporine 53-56 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 130-133 15620875-5 2005 Inhibition of P-gp by cyclosporin A (CsA) significantly reduced secretory flux of compounds known to be P-pg substrates, but only enhanced the absorptive flux of compounds with high efflux ratio (>100). Cyclosporine 22-35 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 14-18 15620875-5 2005 Inhibition of P-gp by cyclosporin A (CsA) significantly reduced secretory flux of compounds known to be P-pg substrates, but only enhanced the absorptive flux of compounds with high efflux ratio (>100). Cyclosporine 37-40 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 14-18 15638085-2 2004 The results showed that CsA combined with Ver or Tet synergistically inhibited P-gp mediated efflux of Rh123 from rat BMEC, suggesting that the combined application of P-gp inhibitors would possibly be a useful approach to increase drug concentration in brain tissues, enhance the therapeutic effect and reduce the toxicity of drugs. Cyclosporine 24-27 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 79-83 15638085-2 2004 The results showed that CsA combined with Ver or Tet synergistically inhibited P-gp mediated efflux of Rh123 from rat BMEC, suggesting that the combined application of P-gp inhibitors would possibly be a useful approach to increase drug concentration in brain tissues, enhance the therapeutic effect and reduce the toxicity of drugs. Cyclosporine 24-27 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 168-172 15482640-9 2004 These results demonstrate that bioavailability of ciclosporin is markedly reduced by MPS pulse treatment, and the mechanism of this interaction was confirmed to involve enhancement of small-intestinal P-gp function and decrease in bile secretion. Cyclosporine 50-61 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 201-205 15039293-5 2004 Moreover, berberine was processed through hepatobiliary excretion against a concentration gradient based on the bile-to-blood distribution ratio (AUC(bile)/AUC(blood)); the active berberine efflux might be affected by P-gp and OCT since coadministration of berberine and CsA or quinidine at the same dosage of 10 mg kg(-1) significantly decreased the berberine amount in bile. Cyclosporine 271-274 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 218-222 15114410-1 2004 PURPOSE: Cyclosporine A (CyA) is able to inhibit P-glycoprotein (P-gp) and to increase cytotoxicity of some anticancer drugs, including etoposide. Cyclosporine 9-23 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 49-63 15114410-1 2004 PURPOSE: Cyclosporine A (CyA) is able to inhibit P-glycoprotein (P-gp) and to increase cytotoxicity of some anticancer drugs, including etoposide. Cyclosporine 9-23 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 65-69 15114410-1 2004 PURPOSE: Cyclosporine A (CyA) is able to inhibit P-glycoprotein (P-gp) and to increase cytotoxicity of some anticancer drugs, including etoposide. Cyclosporine 25-28 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 49-63 15114410-1 2004 PURPOSE: Cyclosporine A (CyA) is able to inhibit P-glycoprotein (P-gp) and to increase cytotoxicity of some anticancer drugs, including etoposide. Cyclosporine 25-28 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 65-69 15187451-6 2004 The apparent uptake of PTZ by the brain increased in the presence of P-gp inhibitors such as cyclosporin A, quinidine, verapamil and vinblastine after the carotid injection. Cyclosporine 93-106 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 69-73 14743973-6 2003 The results indicated that P-gp inhibitors Ery and CsA may increase concentration in rat brain by inhibiting elimination of NMD from brain. Cyclosporine 51-54 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 27-31 14642487-4 2003 Cyclosporin A (CsA) at 0, 10, 15, 25, 35, and 50 mg/kg of body weight was used as a P-gp modulator. Cyclosporine 0-13 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 84-88 14642487-4 2003 Cyclosporin A (CsA) at 0, 10, 15, 25, 35, and 50 mg/kg of body weight was used as a P-gp modulator. Cyclosporine 15-18 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 84-88 12612437-0 2003 Cyclosporine a augments P-glycoprotein expression in the regenerating rat liver. Cyclosporine 0-14 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 24-38 12820149-2 2003 Evaluation was made by measuring the effects of a potent P-gp inhibitor (verapamil, cyclosporin A) on in vitro efflux transport of these compounds across the everted small intestine, on in situ absorption from the small intestine, and on in vivo total plasma clearance (CL(total)) as well as biliary and urinary excretions after intravenous administration. Cyclosporine 84-97 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 57-61 12817897-0 2003 Effect of P-glycoprotein modulator, cyclosporin A, on the gastrointestinal excretion of irinotecan and its metabolite SN-38 in rats. Cyclosporine 36-49 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 10-24 12817897-2 2003 Cyclosporin A (CsA) was used to modulate P-gp and cMOAT/MRP2. Cyclosporine 0-13 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 41-45 12817897-2 2003 Cyclosporin A (CsA) was used to modulate P-gp and cMOAT/MRP2. Cyclosporine 15-18 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 41-45 12626638-8 2003 Potent P-gp inhibitors, such as PSC833 or CsA, partially canceled the asymmetry. Cyclosporine 42-45 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 7-11 12612437-2 2003 Previous studies showed that the immunosuppressive agent cyclosporine A (CsA) modulates P-gp and exerts a hepatotrophic influence in the regenerating liver. Cyclosporine 57-71 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 88-92 12612437-2 2003 Previous studies showed that the immunosuppressive agent cyclosporine A (CsA) modulates P-gp and exerts a hepatotrophic influence in the regenerating liver. Cyclosporine 73-76 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 88-92 12612437-6 2003 In CsA pretreated animals, P-gp levels were increased even in normal hepatocytes by 34%, and an additional augmentation was seen in hepatocytes from 24 and 48 h regenerating livers (60% and 56%, respectively). Cyclosporine 3-6 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 27-31 12612437-7 2003 In summary, we demonstrate for the first time that CsA has an additive effect on the expression of P-glycoprotein during liver regeneration in the rat. Cyclosporine 51-54 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 99-113 12427482-1 2002 Cyclosporin, an immunosuppressant with a narrow therapeutic window, is a substrate for both CYP3A4 and P-glycoprotein (Pgp). Cyclosporine 0-11 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 103-117 12644037-1 2003 Cyclosporine A (CsA) reduces liver canalicular membrane (CM) fluidity to cause a disproportionate reduction of biliary lipid secretion (the uncoupling phenomenon) without affecting adenosine triphosphate-dependent (ABC) transporters except for Mdr1. Cyclosporine 0-14 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 244-248 12644037-1 2003 Cyclosporine A (CsA) reduces liver canalicular membrane (CM) fluidity to cause a disproportionate reduction of biliary lipid secretion (the uncoupling phenomenon) without affecting adenosine triphosphate-dependent (ABC) transporters except for Mdr1. Cyclosporine 16-19 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 244-248 12427482-1 2002 Cyclosporin, an immunosuppressant with a narrow therapeutic window, is a substrate for both CYP3A4 and P-glycoprotein (Pgp). Cyclosporine 0-11 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 119-122 12427482-11 2002 It is suggested that concurrent use of quercetin or quercetin-containing dietary supplement or herbs with cyclosporin or other medications whose absorption and metabolism are mediated by Pgp and/or CYP3A4 should require close monitoring. Cyclosporine 106-117 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 187-190 12466241-0 2002 The effects of the cyclosporin A, a P-glycoprotein inhibitor, on the pharmacokinetics of baicalein in the rat: a microdialysis study. Cyclosporine 19-32 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 36-50 12466241-6 2002 The P-glycoprotein inhibitor cyclosporin A was used to help delineate its roles. Cyclosporine 29-42 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 4-18 12235265-9 2002 Consistent with published reports, sirolimus was a good inhibitor of P-glycoprotein, inhibiting polarized basolateral-to-apical flux of rhodamine 123 with an IC(50) of 0.625 to 1.25 microM (cyclosporine caused >80% inhibition at 5 microM). Cyclosporine 190-202 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 69-83 12405759-0 2002 Determination of naringin in rat blood, brain, liver, and bile using microdialysis and its interaction with cyclosporin a, a p-glycoprotein modulator. Cyclosporine 108-121 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 125-139 12530470-2 2002 The aim of this study was to use the P-glycoprotein (P-glycoprotein) inhibitors cyclosporin A, verapamil and the monoclonal antibody C219 in in vivo and in vitro models of intestinal absorption to determine the role of P-glycoprotein in berberine absorption. Cyclosporine 80-93 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 37-51 12530470-2 2002 The aim of this study was to use the P-glycoprotein (P-glycoprotein) inhibitors cyclosporin A, verapamil and the monoclonal antibody C219 in in vivo and in vitro models of intestinal absorption to determine the role of P-glycoprotein in berberine absorption. Cyclosporine 80-93 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 53-67 12530470-2 2002 The aim of this study was to use the P-glycoprotein (P-glycoprotein) inhibitors cyclosporin A, verapamil and the monoclonal antibody C219 in in vivo and in vitro models of intestinal absorption to determine the role of P-glycoprotein in berberine absorption. Cyclosporine 80-93 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 53-67 12112443-9 2002 In addition, results from functional studies show that the accumulation of the P-glycoprotein substrate digoxin by RBE4 monolayer cells is significantly enhanced in the presence of standard P-glycoprotein inhibitors (verapamil, cyclosporin A, PSC 833), protease inhibitors (saquinavir, ritonavir, indinavir), and the metabolic inhibitor, sodium azide. Cyclosporine 228-241 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 79-93 12113888-1 2002 Cyclosporine A and steroids are effective against rheumatoid arthritis and also known as substrates of P-glycoprotein (P-gp). Cyclosporine 0-14 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 103-117 12113888-1 2002 Cyclosporine A and steroids are effective against rheumatoid arthritis and also known as substrates of P-glycoprotein (P-gp). Cyclosporine 0-14 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 119-123 11861816-2 2002 Plasma concentrations of grepafloxacin and levofloxacin after intravenous and intraintestinal administration were increased by cyclosporin A, a P-glycoprotein inhibitor, in rats. Cyclosporine 127-140 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 144-158 11897974-3 2002 The relation between the chirality of the drug mefloquine and the intracellular concentrations of the drug cyclosporine is illustrated by examining the effect of the enantiomers of mefloquine on the transport activity of P-glycoprotein (Pgp). Cyclosporine 107-119 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 221-235 11897974-3 2002 The relation between the chirality of the drug mefloquine and the intracellular concentrations of the drug cyclosporine is illustrated by examining the effect of the enantiomers of mefloquine on the transport activity of P-glycoprotein (Pgp). Cyclosporine 107-119 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 237-240 11897974-5 2002 The results demonstrated that (+)-mefloquine competitively displaced the Pgp substrate cyclosporine whereas (-)-mefloquine had no effect on cyclosporine-Pgp binding. Cyclosporine 87-99 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 73-76 11918846-1 2002 AIM: To study whether P-glycoprotein (P-gp) inhibitor cyclosporin A (CsA) enhanced the protection of nimodipine (NMD) against brain damage. Cyclosporine 54-67 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 22-36 11918846-1 2002 AIM: To study whether P-glycoprotein (P-gp) inhibitor cyclosporin A (CsA) enhanced the protection of nimodipine (NMD) against brain damage. Cyclosporine 54-67 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 38-42 11918846-1 2002 AIM: To study whether P-glycoprotein (P-gp) inhibitor cyclosporin A (CsA) enhanced the protection of nimodipine (NMD) against brain damage. Cyclosporine 69-72 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 22-36 11918846-1 2002 AIM: To study whether P-glycoprotein (P-gp) inhibitor cyclosporin A (CsA) enhanced the protection of nimodipine (NMD) against brain damage. Cyclosporine 69-72 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 38-42 11918846-10 2002 CONCLUSION: P-gp inhibitor CsA may enhance the protection of NMD against brain damage. Cyclosporine 27-30 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 12-16 11709325-2 2001 The typical substrates for P glycoprotein, i.e., cyclosporine, colchicine, and erythromycin, inhibited the biliary clearance of rhodamine-123, whereas a substrate for organic cation transporter, cimetidine, did not inhibit clearance, suggesting that rhodamine-123 is transported mainly by P glycoprotein. Cyclosporine 49-61 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 27-41 11796340-3 2002 This secretory transport of grepafloxacin was diminished by both probenecid, an MRP2 inhibitor, and cyclosporine, a P-gp inhibitor. Cyclosporine 100-112 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 116-120 11709325-2 2001 The typical substrates for P glycoprotein, i.e., cyclosporine, colchicine, and erythromycin, inhibited the biliary clearance of rhodamine-123, whereas a substrate for organic cation transporter, cimetidine, did not inhibit clearance, suggesting that rhodamine-123 is transported mainly by P glycoprotein. Cyclosporine 49-61 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 289-303 11696858-4 2001 The MDR1 inhibitors cyclosporine A (10 microm) and verapramil (10 microm) inhibited ATP release by 69% and 62%, respectively (p < 0.001). Cyclosporine 20-34 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 4-8 11745716-0 2001 Influence of P-glycoprotein on the transplacental passage of cyclosporine. Cyclosporine 61-73 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 13-27 11745716-8 2001 Our findings indicate that P-glycoprotein pumps cyclosporine out of the trophoblast cells of the rat placenta in the ATP-dependent manner and restricts the passage of cyclosporine across the placental barrier. Cyclosporine 48-60 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 27-41 11745716-8 2001 Our findings indicate that P-glycoprotein pumps cyclosporine out of the trophoblast cells of the rat placenta in the ATP-dependent manner and restricts the passage of cyclosporine across the placental barrier. Cyclosporine 167-179 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 27-41 11557129-3 2001 Inhibitors of mdr1-dependent transport such as verapamil or cyclosporin A have been found to decrease Rh123 efflux from mdr1-expressing cells. Cyclosporine 60-73 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 14-18 11557129-3 2001 Inhibitors of mdr1-dependent transport such as verapamil or cyclosporin A have been found to decrease Rh123 efflux from mdr1-expressing cells. Cyclosporine 60-73 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 120-124 10820430-7 2000 Our functional analysis of P-gp showed a modest effect of P-gp modulators (CsA, verapamil, PSC 833) on the uptake of colchicine (a substrate of P-gp) by astrocytes, whereas they increased by about 50% the uptake of vincristine (a common substrate of P-gp and MRP) by astrocytes. Cyclosporine 75-78 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 27-31 11458978-0 2001 In vivo induction of hepatic p-glycoprotein by cyclosporine in the rat. Cyclosporine 47-59 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 29-43 11458978-1 2001 The objective of the present study was to investigate the regulation of P-glycoprotein by cyclosporine, a known inhibitor of CYP3A, at different dosage levels and lengths of treatment. Cyclosporine 90-102 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 72-86 11458978-6 2001 Significant induction of hepatic P-glycoprotein was found in rats given cyclosporine. Cyclosporine 72-84 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 33-47 11458978-8 2001 Low doses of cyclosporine also induced P-glycoprotein but not to a significant extent, indicating a dose-dependent effect. Cyclosporine 13-25 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 39-53 11458978-10 2001 Fourteen days after the discontinuation of cyclosporine treatment, P-glycoprotein levels returned to near the control values. Cyclosporine 43-55 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 67-81 11458978-11 2001 As a drug efflux transporter, the induction of P-glycoprotein by cyclosporine may decrease the hepatic metabolism of P-glycoprotein substrates. Cyclosporine 65-77 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 47-61 11458978-11 2001 As a drug efflux transporter, the induction of P-glycoprotein by cyclosporine may decrease the hepatic metabolism of P-glycoprotein substrates. Cyclosporine 65-77 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 117-131 11458978-12 2001 Therefore this induction of hepatic P-glycoprotein and suppression of hepatic CYP3A may have a coordinate effect on the metabolism of cyclosporine. Cyclosporine 134-146 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 36-50 11113570-9 2000 The efflux of [(14)C]mefloquine from GPNT cells was decreased when the cells were incubated with the P-gp modulators, verapamil, cyclosporin A or chlorpromazine, suggesting that MQ could be a P-gp substrate. Cyclosporine 129-142 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 101-105 11113570-9 2000 The efflux of [(14)C]mefloquine from GPNT cells was decreased when the cells were incubated with the P-gp modulators, verapamil, cyclosporin A or chlorpromazine, suggesting that MQ could be a P-gp substrate. Cyclosporine 129-142 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 192-196 11334874-0 2001 Chronic cyclosporine administration induces renal P-glycoprotein in rats. Cyclosporine 8-20 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 50-64 11334874-1 2001 The effect of cyclosporine doses on renal P-glycoprotein expression was examined. Cyclosporine 14-26 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 42-56 11334874-5 2001 Western blot analysis showed that cyclosporine administered orally at 10 and 30 mg/kg/day and subcutaneously at 15 mg/kg/day induced significantly renal P-glycoprotein expression. Cyclosporine 34-46 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 153-167 11334874-6 2001 After discontinuation of cyclosporine, renal P-glycoprotein returned to pre-dosing levels in oral groups, whereas the return was incomplete in subcutaneous groups. Cyclosporine 25-37 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 45-59 11334874-7 2001 These results indicate that cyclosporine induces renal P-glycoprotein overexpression a dose-dependent manner. Cyclosporine 28-40 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 55-69 11237863-10 2001 Only expression of the transporter P-glycoprotein was increased by cyclosporin A. Cyclosporine 67-80 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 35-49 11217075-5 2001 TM-BBB cells are able to undergo efflux transport of cyclosporin A, which is a substrate for P-gp transport activity. Cyclosporine 53-66 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 93-97 11068023-6 2000 Modulation of P-glycoprotein was achieved by injection of cyclosporin A (50 mg/kg) 30 min prior to injection of [18F]MPPF.The distribution of 18F-derived radioactivity corresponded to regional 5-HT1A receptor density as known from autoradiography. Cyclosporine 58-71 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 14-28 11068023-7 2000 Modulation of P-glycoprotein with cyclosporin A caused a 5- to 10-fold increase in the uptake of [18F]MPPF. Cyclosporine 34-47 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 14-28 11033075-7 2000 When verapamil or cyclosporin A, potent modulators of P-gp, was added to the apical medium together with unlabeled VLB, enhanced basolateral-to-apical transport of [3H]VLB was disappeared. Cyclosporine 18-31 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 54-58 10901449-8 2000 Uptake in hooded rat sarcoma (HSN) cells, which express Pgp, is significantly increased in the presence of the MDR modulator cyclosporin A. Cyclosporine 125-138 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 56-59 10820430-7 2000 Our functional analysis of P-gp showed a modest effect of P-gp modulators (CsA, verapamil, PSC 833) on the uptake of colchicine (a substrate of P-gp) by astrocytes, whereas they increased by about 50% the uptake of vincristine (a common substrate of P-gp and MRP) by astrocytes. Cyclosporine 75-78 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 58-62 10820430-7 2000 Our functional analysis of P-gp showed a modest effect of P-gp modulators (CsA, verapamil, PSC 833) on the uptake of colchicine (a substrate of P-gp) by astrocytes, whereas they increased by about 50% the uptake of vincristine (a common substrate of P-gp and MRP) by astrocytes. Cyclosporine 75-78 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 58-62 10820430-7 2000 Our functional analysis of P-gp showed a modest effect of P-gp modulators (CsA, verapamil, PSC 833) on the uptake of colchicine (a substrate of P-gp) by astrocytes, whereas they increased by about 50% the uptake of vincristine (a common substrate of P-gp and MRP) by astrocytes. Cyclosporine 75-78 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 58-62 10648640-5 2000 The Mdr1 modulators cyclosporin A and vinblastine did not inhibit binding, which is different from Mdr1. Cyclosporine 20-33 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 4-8 10700027-5 2000 CsA increased this uptake 5-6-fold, not only due to P-gp modulation in the BBB but also to a 2-fold higher plasma AUC. Cyclosporine 0-3 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 52-56 10700027-7 2000 These results indicate that the cerebral uptake of beta-adrenoceptor ligands can be increased by administration of P-gp modulators such as CsA without affecting regional distribution in the brain. Cyclosporine 139-142 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 115-119 10537053-7 1999 Furthermore, the P-gp blocker cyclosporin A induced a large increase in apical to basal permeability of vincristine. Cyclosporine 30-43 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 17-21 9862768-4 1999 Ileal ranitidine secretion was concentration dependent and significantly reduced by the P-glycoprotein (P-gp) substrates verapamil and cyclosporin. Cyclosporine 135-146 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 88-102 10455332-4 1999 In the presence of quinidine, verapamil and cyclosporin (substrates of the P-glycoprotein (P-gp)), plasma AUCs of ciprofloxacin were 1.5 - 2 fold increased, while biliary clearance (1.5 - 2 fold), intestinal overall and net clearances (2 - 4 fold and 1.5 - 8 fold respectively) decreased. Cyclosporine 44-55 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 75-89 9862768-4 1999 Ileal ranitidine secretion was concentration dependent and significantly reduced by the P-glycoprotein (P-gp) substrates verapamil and cyclosporin. Cyclosporine 135-146 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 104-108 9806956-1 1998 PSC 833, a nonimmunosuppressive cyclosporin, is a potent inhibitor of the efflux of antitumor drugs mediated by P-glycoprotein and thus has been introduced in clinical trials as an agent to overcome multidrug resistance. Cyclosporine 32-43 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 112-126 9821664-3 1998 Co-administration of cyclosporin, a P-glycoprotein inhibitor, significantly reduced tubular secretion of rhodamine 123. Cyclosporine 21-32 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 36-50 9610733-7 1998 In vitro experiments performed with renal BBMs showed that the inhibition of P-gp photolabeling by cyclosporin A (CsA), verapamil and vinblastine could be reversed by performing washing steps to remove these drugs before incubating the samples with IAAP. Cyclosporine 99-112 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 77-81 9751629-11 1998 This resistance is reversible by the Pgp-reversing agents cyclosporin A, PSC833, and verapamil, suggesting a conservation in some functions of Pgps across large evolutionary distance. Cyclosporine 58-71 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 37-40 9610733-7 1998 In vitro experiments performed with renal BBMs showed that the inhibition of P-gp photolabeling by cyclosporin A (CsA), verapamil and vinblastine could be reversed by performing washing steps to remove these drugs before incubating the samples with IAAP. Cyclosporine 114-117 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 77-81 9610733-9 1998 Pre-incubation of intact CHRC5 cells with PSC, CsA and verapamil also inhibited P-gp photolabeling and increased rhodamine 123 accumulation. Cyclosporine 47-50 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 80-84 9525837-0 1998 Modulation of doxorubicin concentration by cyclosporin A in brain and testicular barrier tissues expressing P-glycoprotein in rats. Cyclosporine 43-56 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 108-122 9458727-4 1998 However, the development of fluorescence was accelerated two- to threefold by substrates and/or inhibitors of MDR1, such as verapamil, tamoxifen, and cyclosporin A, and by addition of the transport-blocking antibody to MDR1, UIC2. Cyclosporine 150-163 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 110-114 9403721-1 1997 P-glycoprotein (P-gp) expels hydrophobic substances from the cell, including chemotherapeutic agents and immunosuppressants such as cyclosporin A (CsA) and FK506. Cyclosporine 132-145 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 0-14 9403721-1 1997 P-glycoprotein (P-gp) expels hydrophobic substances from the cell, including chemotherapeutic agents and immunosuppressants such as cyclosporin A (CsA) and FK506. Cyclosporine 132-145 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 16-20 9403721-1 1997 P-glycoprotein (P-gp) expels hydrophobic substances from the cell, including chemotherapeutic agents and immunosuppressants such as cyclosporin A (CsA) and FK506. Cyclosporine 147-150 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 0-14 9403721-1 1997 P-glycoprotein (P-gp) expels hydrophobic substances from the cell, including chemotherapeutic agents and immunosuppressants such as cyclosporin A (CsA) and FK506. Cyclosporine 147-150 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 16-20 9403721-2 1997 Exposure of cultured renal tubular cells to CsA induces P-gp overexpression in cell membranes. Cyclosporine 44-47 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 56-60 9403721-7 1997 Treatment with CsA induced overexpression of P-gp in tubular cells of the kidney that increased with time. Cyclosporine 15-18 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 45-49 9403721-12 1997 These results support the hypothesis that the role of P-gp as a detoxicant in renal cells may be related to mechanisms that control the cytoplasmic removal of both toxic metabolites from CsA and those originating from the catabolism of signal transduction proteins (methylcysteine esters), which are produced as a result of ras activation in presence of angiotensin II. Cyclosporine 187-190 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 54-58 9374872-0 1997 P-glycoprotein is a dimer in the kidney and brain capillary membranes: effect of cyclosporin A and SDZ-PSC 833. Cyclosporine 81-94 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 0-14 9374872-9 1997 P-gp expressed in renal BBMs isolated from rats which had been treated daily with cyclosporin A (CsA) or PSC also migrated as a 264 kDa protein. Cyclosporine 82-95 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 0-4 9374872-9 1997 P-gp expressed in renal BBMs isolated from rats which had been treated daily with cyclosporin A (CsA) or PSC also migrated as a 264 kDa protein. Cyclosporine 97-100 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 0-4